Cheddar News' stock of the day is Moderna following promising results from a cancer vaccine study.

Stock of the Day: Moderna Shares Soar as Cancer Vaccine Shows Promise

Well let's take a look at our stock of the day. We're focusing on Moderna's shares pop following some promising results from one of its new therapies, a new cancer vaccine from Moderna using the same M. RNA technology as the Covid 19 shots, showing huge promise. In a recent study, melanoma patients, risk of death or relapse 44% lower when taking the vaccine paired with an immunotherapy cancer treatment from Merck called keytruda. Well, the vaccine is individually customized for each patient using data from the patient's tumor to create a boost for the immune system to fight the cancer. And while the study only looked at 100 and 50 people and is yet to be reviewed independently, it could represent a big breakthrough and cancer treatment, Mark and Modern are planning a larger study next year expanding to additional tumor types. If it does show similar success, it could pave the way for the first M. RNA cancer vaccine and as expected shares of Moderna popping on today's news of 19%. With just a few minutes left in the trading session. Of course, Moderna has been focused still the Covid 19 vaccines and this comes on the heels of the FDA and CDC approving um a chrome boosters for kids ages six months to five years old. So let's take a look at who's eligible Children ages six months to five years old, who received Moderna's or Pfizer's original two dose series eligible for the oh Macron booster. The Children who receive Pfizer's booster and not eligible for the new shop because appending data for the booster dose. While Moderna is still gaining revenue from its vaccines as infections are on the rise in the past month, analysts say the company still has to prove itself in a post pandemic world. Well, it's GPS numbers are expected to show a 24% slowdown in 2022 following a banner 2021 as its selling fewer vaccines and vaccine competitor fights. There is a well established company with a diverse line of drugs and treatments so it shouldn't have trouble keeping momentum. But Madeira focusing mostly on new M. RNA therapies which outside of the covid 19 vaccine are largely in the research and development phase. And I'll take a look at the stock here the past six months up a whopping 54%. A very nice rally with momentum heading into the new year. Uh quite impressive considering just how much stocks have fallen this year. So this this name is certainly outperforming the broader market